USS Investment Management Ltd acquired a new stake in Pfizer (NYSE:PFE) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 185,300 shares of the biopharmaceutical company’s stock, valued at approximately $6,718,000.
Several other hedge funds have also recently bought and sold shares of PFE. Peregrine Asset Advisers Inc. lifted its holdings in shares of Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC lifted its holdings in shares of Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 50 shares during the period. Stone House Investment Management LLC lifted its holdings in shares of Pfizer by 1.0% during the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 72 shares during the period. Highland Private Wealth Management lifted its holdings in shares of Pfizer by 0.8% during the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 76 shares during the period. Finally, Autus Asset Management LLC lifted its holdings in shares of Pfizer by 1.2% during the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 78 shares during the period. 71.20% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently weighed in on PFE. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, April 2nd. Barclays downgraded Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $41.00 to $38.00 in a report on Thursday. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Finally, UBS set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company. Pfizer has an average rating of “Hold” and an average price target of $39.25.
In related news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares in the company, valued at approximately $1,374,505.21. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mikael Dolsten sold 69,699 shares of Pfizer stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,037 shares of company stock valued at $9,064,785. Company insiders own 0.06% of the company’s stock.
Shares of PFE stock opened at $35.17 on Friday. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The firm has a market capitalization of $215,077.02, a PE ratio of 13.27, a PEG ratio of 1.80 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the business posted $0.47 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. sell-side analysts anticipate that Pfizer will post 2.96 earnings per share for the current fiscal year.
Pfizer announced that its board has approved a share repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/uss-investment-management-ltd-takes-6-72-million-position-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.